NEW YORK (GenomeWeb) – With the launch last year of its PCR-based GeneStrat liquid biopsy test for non-small cell lung cancer and the release of a next-generation sequencing test planned for later this year, Biodesix continues to expand its offerings with the aim of addressing additional points in the NSCLC care pathway.

According Paul Beresford, the company's chief business officer, the move into genetic testing has also helped drive sales of Biodesix's flagship product, Veristrat, a proteomic test for assessing a patient's prognosis and predicting response to drug treatment.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.

Sponsored by

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.